Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Zacks Investment Research on MSN
Novavax grants license for use of Matrix-M adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
JDK 27, due in September, kicks off with a post-quantum hybrid key exchange proposal to bolster the security of network ...
OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results